Class information for:
Level 1: PANITUMUMAB//CETUXIMAB//METASTATIC COLORECTAL CANCER

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1661 2469 40.5 85%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
580 13536 MICROSATELLITE INSTABILITY//LYNCH SYNDROME//HNPCC

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PANITUMUMAB Author keyword 256 69% 9% 219
2 CETUXIMAB Author keyword 136 28% 17% 409
3 METASTATIC COLORECTAL CANCER Author keyword 120 40% 10% 235
4 KRAS Author keyword 108 28% 14% 334
5 KRAS MUTATION Author keyword 30 39% 2% 61
6 DIGEST ONCOL UNIT Address 22 32% 2% 58
7 CLINICAL COLORECTAL CANCER Journal 21 22% 3% 85
8 B RAF Author keyword 19 11% 6% 155
9 REGORAFENIB Author keyword 18 41% 1% 34
10 FOLFIRI Author keyword 16 32% 2% 42

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 PANITUMUMAB 256 69% 9% 219 Search PANITUMUMAB Search PANITUMUMAB
2 CETUXIMAB 136 28% 17% 409 Search CETUXIMAB Search CETUXIMAB
3 METASTATIC COLORECTAL CANCER 120 40% 10% 235 Search METASTATIC+COLORECTAL+CANCER Search METASTATIC+COLORECTAL+CANCER
4 KRAS 108 28% 14% 334 Search KRAS Search KRAS
5 KRAS MUTATION 30 39% 2% 61 Search KRAS+MUTATION Search KRAS+MUTATION
6 B RAF 19 11% 6% 155 Search B+RAF Search B+RAF
7 REGORAFENIB 18 41% 1% 34 Search REGORAFENIB Search REGORAFENIB
8 FOLFIRI 16 32% 2% 42 Search FOLFIRI Search FOLFIRI
9 MCRC 14 59% 1% 16 Search MCRC Search MCRC
10 KRAS WILD TYPE 14 100% 0% 7 Search KRAS+WILD+TYPE Search KRAS+WILD+TYPE

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CETUXIMAB PLUS IRINOTECAN 350 72% 11% 277
2 PANITUMUMAB 325 72% 10% 252
3 CETUXIMAB 236 34% 23% 573
4 1ST LINE TREATMENT 106 16% 25% 613
5 PLUS IRINOTECAN 86 30% 10% 245
6 LEUCOVORIN 72 14% 19% 475
7 KRAS WILD TYPE 72 93% 1% 27
8 OXALIPLATIN 68 15% 17% 424
9 KIRSTEN RAS MUTATIONS 67 63% 3% 67
10 WILD TYPE KRAS 55 77% 1% 37

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CLINICAL COLORECTAL CANCER 21 22% 3% 85

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials 2015 12 15 100%
Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis 2015 5 32 78%
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis 2014 20 36 86%
BRAF(V600E) Mutation and Its Association with Clinicopathological Features of Colorectal Cancer: A Systematic Review and Meta-Analysis 2014 20 36 67%
Metastatic Colorectal Cancer: Current State and Future Directions 2015 2 51 80%
Clinical relevance of KRAS mutations in codon 13: Where are we? 2014 10 44 84%
A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer 2014 8 18 83%
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review 2014 10 88 69%
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor-Targeted Therapy in Metastatic Colorectal Cancer 2009 268 103 63%
Colon Cancer, Version 3.2014 2014 14 189 50%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 DIGEST ONCOL UNIT 22 32% 2.3% 58
2 FALCK MED ONCOL 14 51% 0.8% 19
3 DNA REPAIR GENOME STABIL RADIAT ONCOL 14 100% 0.3% 7
4 RADIAT ONCOL MED PHYS BIOPHYS 6 100% 0.2% 4
5 UMR CRAN 7039 6 100% 0.2% 4
6 EXPT CLIN MED SURG F MAGRASSI A LANZAR 5 60% 0.2% 6
7 MOL DIGEST ONCOL 5 60% 0.2% 6
8 NIGUARDA CANC 5 41% 0.4% 9
9 UNIT MED ONCOL 1 5 55% 0.2% 6
10 SHARON CARPENTER 4 67% 0.2% 4

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000173959 OXALIPLATIN//CAPECITABINE//IRINOTECAN
2 0.0000118841 NIMOTUZUMAB//H R3//CETUXIMAB
3 0.0000104005 KIAA1199//MIR 188 5P//TRANSCRIPTOMIC PROFILES
4 0.0000103660 SERRATED ADENOMA//SESSILE SERRATED ADENOMA//TRADITIONAL SERRATED ADENOMA
5 0.0000092414 COLORECTAL LIVER METASTASES//LIVER METASTASES//LIVER RESECTION
6 0.0000076007 OREGOVOMAB//AFLIBERCEPT//GI PERFORATION
7 0.0000073424 EGF POLYMORPHISM//GEFITINIB THERAPY//INTRON 1 POLYMORPHISM
8 0.0000071905 DNA MULTIPLOIDY//DNA PLOIDY//DNA PLOIDY HETEROGENEITY
9 0.0000068429 TSU 68//APATINIB//MUCOCUTANEOUS TOXICITIES
10 0.0000064073 GEFITINIB//ERLOTINIB//EGFR MUTATION